<!DOCTYPE html>

<html> 

<head> <!-- /main page header -->
  <meta charset="UTF-8">
   <meta name="format-detection" >
   <meta name="viewport" content="user-scalable=no, initial-scale=5, minimum-scale=1, maximum-scale=5">
   <title>BD-MIMS</title>
   <link rel="stylesheet" href="css/main.css">
   <link rel="stylesheet" href="css/themes/default/jquery.mobile-1.3.1.min.css">
   <script src="js/jquery.js"></script>
   <script src="js/jqm.js"></script>
   <script scr="js/cordova.js"type="text/javascript"></script>
   <script>
    function init() {
      document.addEventListener("deviceready", onDeviceReady, false);
    }

    function onDeviceReady() {
      alert('Damn Niagga, its playtime!');
    }
  </script>
   
</head> <!-- /main page header -->


<body onload="init()"> 



<div data-role="page" id="" data-theme="a"> <!-- /first page -->


    <div data-role="header"> <!-- /this is header -->
      <h1>   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>

    </div> <!-- /this is header -->


<div data-role="content" data-theme="a">  <!-- /content div -->
  

<ul data-role="listview" data-inset="true" data-theme="b">                 
  <li><a href="#URINARY">URINARY ANTI- INFECTIVES</a></li> 
  <li><a href="#RETENTION">URINARY RETENTION: BENIGN PROSTATIC HYPERPLASIA</a></li> 
  <li><a href="#HAEMODIALYSIS SOLUTIONS">HAEMODIALYSIS SOLUTIONS</a></li> 
  <li><a href="#GENITAL">DRUGS USING IN GENITAL PROBLEMS</a></li>

</ul>

  
</div> <!-- content div -->

   <div data-role="footer"data-position="fixed"> <!-- /first footer -->
      <h4></h4>
   </div><!-- /first footer -->
  </div> <!-- /first page -->
 
  <!-- /page snippet -->

<!-- /................page............................ -->


<div data-role="page" id="URINARY" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  URINARY ANTI- INFECTIVES  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 


<a href="#" data-role="button" data-theme="a"> 
    Systemic Urinary Anti- infectives </a>
      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> NALIDIXIC ACID: Tablet/Suspension  </h3>
          <p> <strong>Ind:</strong> Urinary tract infections (acute & chronic); shigellosis.<br><br>

          <strong>C/I:</strong> Infants under 3 months, epilepsy and
          convulsive disorders, CNS lesions.<br><br>

          <strong>S/E:</strong> G.I. disturbances including nausea, vomiting, diarrhoea; haemolysis in G6PD deficiency; allergic reactions including urticaria, rashes, fever, arthralgia, eosinophylia, also myalgia, muscle weakness, phototoxicity, jaundice, visual disturbances,convulsions.<br><br>

          <strong>Precautions:</strong> Impaired hepatic or renal function, breast feeding, avoid strong sunlight, interference with biochemical tests using copper salts (e.g.Benedict's test)<br><br>

          <strong>Dosage & admin:</strong> Adult: Acute infections: 1gm every 6 hours daily for minimum 7 days, reducing to 500mg every 6 hours.
          Chronic infections: 500mg every 6 hours daily. <br><br>

          <strong>Children:</strong>: Under 3 months not recommended; 3 months-12 years upto 50mg/kg body-wt. daily in divided doses (6 hourly)   </p>
        </div><!-- collapsible -->
        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEGRAM Tab. Doctor's</h3>
            <p>Nalidixic acid 500mg/tablet. 100's pack: 387.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DEGRAM Susp. Doctor's</h3>
            <p>Nalidixic acid 300mg/5ml: suspension 50ml bot: 30.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIXICON Tab. Jayson</h3>
            <p>Nalidixic acid 500mg/tablet 100's pack: 319.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIXICON Susp. Jayson</h3>
            <p>Nalidixic acid 300mg/5ml: suspension 50ml bot: 30.34 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NALIDEX Tab. Ambee</h3>
            <p>Nalidixic acid 500mg/tablet
        100's pack: 406.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NALIDEX Susp. Ambee</h3>
            <p>Nalidixic acid 250mg/5ml: suspension 50ml bot: 30.34 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NALIDIXIN Tab. Pharmadesh</h3>
            <p>Nalidixic acid 500mg/tablet.
        50's pack: 200.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NALIDIXIN Susp. Pharmadesh</h3>
            <p>Nalidixic acid 300mg/5ml: suspesion 50ml bot: 30.99 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NALID Tab. Square</h3>
            <p>Nalidixic acid 500mg/tablet
        56's pack: 227.36 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NALID Syp. Square</h3>
            <p>Nalidixic acid 300mg/5ml: syrup 50ml bot: 30.34 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NALIGRAM Tab. Acme</h3>
            <p>Nalidixic acid 500mg/tablet 100's pack: 384.00.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NALIGRAM Susp. Acme</h3>
            <p>Nalidixic acid 300mg/5ml: suspension
        50ml bot: 30.34 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NALITRUM Susp. Salton</h3>
            <p>Nalidixic acid 300mg/5ml: suspesion.
        50ml bot: 30.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NALIX Susp. Aristopharma</h3>
            <p>Nalidixic acid 300mg/5ml: suspesion. 50ml bot: 30.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NEBACTIL Susp. Beximco</h3>
            <p>Nalidixic acid 250mg/5ml: suspesion. 50ml bot: 30.36 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ULTRAGRAM Tab. Globe Pharma</h3>
            <p>Nalidixic acid 500mg/tablet 100's pack: 400.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>ULTRAGRAM Susp. Globe Pharma</h3>
            <p>Nalidixic acid 300mg/5ml: suspesion. 50ml bot: 30.00 MRP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set --> 



<a href="#" data-role="button" data-theme="a">  </a>
      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> NITROFURANTOIN: Tablet/Capsule/Suspension  </h3>
        <p>Nitrofurantoin is an antibacterial agent specific for urinary tract infections. It is highly soluble in urine Nitrofurantoin may be available in the form of tablet capsule & suspension.<br><br>

        <strong>Mode of action:</strong> Nitrofurantoin inactivates or alters bacterial ribosomal proteins & other macromolecules. Nitrofurantion has been shown to be active against the following bacteria: Gram- positive aerobes- Staphylococcus saprophyticus, Coagulase-negative staphylococccus aureus, Staphylococcus epidermidis, Group D streptococci, Viridans group streptococci. Gram- negative aerobes: Escherichia coli, Citrobacter amalonaticus, Citrobacter diversus, Citrobacter freundii, Klebsiella oxitoca, Klebsiella ozaenaa.<br><br>

        <strong>Ind:</strong> Urinary tract infections.<br><br>

        <strong>C/I:</strong> Impaired renal functions, anuria, oliguria; infants less then 1 month old; glucose 6-phosphate dehydrogenase deficiency.<br><br>

        <strong>S/E:</strong> Nausea, vomiting,rahses, peripheral neuropathy, pulmonary infiltration, allergic liver damage, peripheral neuropathy, angioedema, rash, pruritus, exfoliative dermatitis, erythema multiforme, pancreatitis, arthralgia, blood disorder, trasient alopecia.<br><br>

        <strong>Precaution:</strong> Ineffective in alkaline urine;pregnanacy.  <br><br>

        <strong>Pregnancy & lactation:</strong> There are no adequate & well-controlled studies in pregnant woman. This drug should be used during pregnancy only if clearly needed.Nitrofurantoin has been detected in human breast milk in trace amounts. Because of the potential for serious adverse reactions from nitrofurantoin in nursing infants under one month of age, a decision should be made whether to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother.<br><br>

        <strong>Dosage & admin:</strong> Adult: 50-100mg every 6 hourly daily with meals or milk for 14 days. In chronic infections, 100-200mg daily. The lower dosage level is recommended for uncomplicated urinary tract infections.For long-term suppressive therapy in adults, a reduction of dosage to 50-100mg at bedtime may be adequate.<br><br>

        <strong>Children:</strong>: Infants less than 1 month (or under 2.5 kg) not recommended. Others, acute infections- 5-7mg/kg/day in 4 divided doses; chronic infections, 2-4mg/kg/day in 4 divided doses. For long-term suppressive therapy in children, doses as low as 1mg/kg/day, given in a single dose or in 2 divided doses, may be adequate.<br><br>

       <strong>Drug inter:</strong> Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate & extent of absorption. Uricosuric drugs, such as probenecid & sulphinpyrazone can inhibit renal tubular secretion of nitrofurantoin.    </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>NINTOIN Tab. Incepta</h3>
            <p>Nitrofurantoin USP 100mg/tablet. 30's pack: 120.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>OFURAN SR Tab. Pacific</h3>
            <p>Nitrofurantoin USP 100mg/tablet (sustained</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->       
   



<a href="#" data-role="button" data-theme="a"> Irrigation Soln. used in Urological Surgery </a>
      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> GLYCINE IRRIGATION SOLN: Injection  </h3>
          <p>  Glycine 1.5% irrigation soln. in water for injection.<br><br>

           <strong>Ind:</strong> Bladder irrigation during urological surgery. (Endoscopic surgery within the urinary tract requires an isotonic irrigant since there is a high risk of fluid absorption. Glycine 1.5% solution is the irrigant of choice for transurethral resection of the prostate gland and bladder tumour. Sterile normal saline is usually used for percutaneous renal surgery).<br><br>

          <strong>S/E; Cautions:</strong> No significant side-effect is noted. 
          <br><br>

          <strong>Use & admin:</strong> Irrigation solution is administered as drip through the bi-luminal catheter and can be continued as required  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>GLYCINE IRRIGATION Soln. Opsosaline</h3>
            <p>Glycine 1.5% irrigation soln. in water for injection. 1000ml bag: 70.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>IRIGON Soln. Beximco</h3>
            <p>Glycine 1.5% irrigation soln. in water for injection. 1000ml bag: 70.79 IP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->

    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->


<div data-role="page" id="RETENTION" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> URINARY RETENTION: BENIGN PROSTATIC HYPERPLASIA </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 

<a href="#" data-role="button" data-theme="a">  </a>
    <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3>FINASTERIDE: Tablet   </h3>
          <p> It is an androgen-antagonist, and used in the treatment of benign prostatic hyperplasia. It specifically inhibits the enzyme 5 a-reductase which metabolises testosterone into the more potent androgen- dehydrotestoste-rone. This anti- androgen action thus leads to reduction in prostate size, with improvement in urinary flow, rate & obstructive symptoms.<br><br>

          <strong>Ind:</strong> Benign prostatic hyperplasia.<br><br>

          <strong>Precautions:</strong> Obstructive uropathy, prostate cancer (may decrease markers such as prostate specific antigen); use of condoms recommended if sexusal partner is pregnant or is likely to become pregnant (finasteride is excreted in semen); women of child-bearing potential should avoid handling crushed or broken tablets.<br><br>

          <strong>S/E:</strong> Impotence, decreased libido and ejaculate volume, breast tenderness and enlargement, hypersensitivity reactions (including lip swelling and rash).<br><br>

          <strong>Dosage & admin:</strong> 5mg daily, review treatment after 6 months (may require several months treatment before benefit is obtained).   </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PRONOR Tab. Square</h3>
            <p>Finasteride 5mg/tablet
        30's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PROSFIN Tab. Beximco</h3>
            <p>Finasteride 5mg/tablet 30's pack: 300.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>RECUR Tab. Beximco</h3>
            <p>Finasteride 1mg/tablet 30's pack: 120.00 IP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->


<a href="#" data-role="button" data-theme="a">  </a>
    <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> OXYBUTYNIN CHLORIDE  </h3>
          <p> OXYBUTYNIN CHLORIDE: Tablet<br><br>
Oxybutynin is an antispasmodic, anticholinergic agent. It is available as oxybutynin chloride 5mg once-a-day controlled release tablet.<br><br>
Mode of action: Oxybutynin chloride relaxes bladder smooth muscles in patients with conditions characterized by involuntary bladder contractions. It increases bladder (vesical) capacity, diminishes the frequency of uninhibited contractions of the detrusor muscle, and delays the initial desire to void. This drug thus decreases urgency and the frequency of both incontinent episodes and voluntary urination.<br><br>

<strong>Ind:</strong> Oxybutynin chloride is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency for urination, frequent urination and nocturnal enuresis.<br><br>

<strong>C/I:</strong> Oxybutynin is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrowangle glaucoma and in patients who are at risk for these conditions. Oxybutynin is also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product.<br><br>

<strong>S/E:</strong> The most common side effects reported are due to anticholinergic effects, such as- dry mouth (which is dose-related), abdominal pain, dry nasal and sinus mucous membranes, back pain, hypertension, palpitation, vasodilatation, flatulence, gastroespohageal reflux, insomnia, nervousness, confusion, cough, sinusitis, bronchitis, dry skin, rash, impaired urination (hesitancey), urinary retention, etc. <br><br>

<strong>Precautions:</strong> Oxybutynin chloride should be used with caution in patients with hepatic or renal impairment, clinically significant bladder outflow obstruction because of the risk of urinary retention, gastrointestinal obstructive disorders becuase of the risk of gastric retention, conditions such as ulcerative colitis, intestinal atony, and myasthenia gravis, gastroesophageal reflux and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate esophagitis.<br><br>

<strong>Pregnancy & lactation:</strong> The safety of oxybutynin administration to women who are or who may become pregnant has not been established. Therefore, oxybutynin should not be given to pregnant women unless, in the judgement of the physician, the probable clinical benefits outweigh the possible hazards. It is not known whether oxybutynin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when oxybutynin is administered to a nursing woman.<br><br>

<strong>Dosage & admin:</strong> Oxybutynin chloride may be administered with or without food. The recommended starting dose is 5mg once daily. Dosage may be adjusted in 5mg increments to achieve a balance of efficacy and tolerability
(up to a maximum of 30mg/day). In general, dosage adjustment may proceed at approximately weekly intervals.<br><br>

<strong>Drug inter:</strong> The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, drowsiness, and/or other anticholinergic-like effects may increase the fequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administerd drugs due to anticholinergic effects on gastrointestinal motility. Pharmacokinetic studies with patients concomitantly receiving cytochrome P450 enzyme inhibitors, such as antimycotic agents (e.g ketoconazole, itraconazole, and miconazole) or macrolide antibiotics (e.g erythromycin and clarithromycin), havd not been performed. No specific drug interaction studies have been performed with oxybutynin.   </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>URICON Tab. Beximco</h3>
            <p>Oxybutynin chloride 5mg/tablet (controlled release)
        30's pack: 180.00 IP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->


<a href="#" data-role="button" data-theme="a">  </a>
    <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> TAMSULOSIN  </h3>
          <p> TAMSULOSIN HCI: Capsule/Tablet.<br><br>
Tamsulosin is a sulfonamethylamine derivative a1A-adrenergic blocking agent. Clinically found useful in the conservative treatment of benign prostatic hyperplasia.<br><br>

<strong>Mode of action:</strong> The drug is pharmaco-logically related to doxazosin, prazosin, and terazosin; but, unlike these drugs, tamsulosin has higher affinity and selectivity for a1A-adrenergic receptors,which are mainly located in nonvascular smooth muscle (e.g prostate), than for a1B-adrenergic receptors located in vascular smooth muscle (e.g internal iliac artery). Such selectivity of tamsulosin for a1A-receptors may result in a reduced incidence of adverse cardiovascular effects (e.g syncope, dizziness, hypotension). The selective affinity of tamsulosin for a1A-adrenergic receptors, located mainly in the prostate causes relaxation of smooth muscle in benign prostatic hyperplasia producing an increase in urinary flow- rate and an improvement in obstructive symptoms.<br><br>

<strong>Ind:</strong> Tamsulosin is used in benign prostatic hyperplasia. It relaxes smooth muscle in benign prostatic hyperplasia producing an increase in urinary flow-rate and an improvement in obstructive symptoms.<br><br>

<strong>C/I:</strong> Tamsulosin should be avoided in patients with a history of orthostatic hypotension and micturition syncope.<br><br>

<strong>S/E:</strong> Side effects of tamsulosin include drowsiness, asthenia, depression, headache, dry mouth, nausea, vomiting, diarrhea, constipation, oedema, blurred vision, rhinitis, erectile disorders, tachyca-rdia and palpitations. Hypersensitivity reactions including rash, pruritus, angioe-dema have been reported in some cases.<br><br>

<strong>Precaution:</strong> Caution may be required in the elderly and in patients with hepatic impairment and severe renal impairment.<br><br>

<strong>Pregnancy & lactation:</strong> Not applicable.<br><br>

<strong>Dosage & admin:</strong> Tamsulosin 0.4mg (tablet or capsule) once daily is recommended as the dose for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). It should be administered approximately one and half hour following the same meal each day. For those patients who fail to respond to the 0.4mg dose after 2 to 4 weeks of treatment, the dose can be increased to 0.8mg once daily.<br><br>

<strong><strong>Drug inter:</strong></strong> The pharmacokinetic & pharmacodynamic interactions between tamsulosin and other a-adrenergic blocking agents have not been determined. However, interactions may be expected and it should not be used in combination with other a-adrenergic blocking agents. The pharmacokinetic interaction between cimetidine and tamsulosin was investigated, the results indicated significant changes in tamsulosin clearance (26% decrease) and AUC. Therefore, tamsulosin should be used with caution in combination with cimetidine, particularly at doses higher than 0.4mg. Caution should be exercised with concomitant administration of warfarin and tamsulosin.   </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>MAXFLO-U Cap. Rangs Pharma</h3>
            <p>Tamsulosin hydrochloride INN 0.4mg/ capsule. 28's pack: 280.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>MAXRIN Cap. Square</h3>
            <p>Tamsulosin hydrochloride INN 0.4mg/ capsule. 20's pack: 240.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PROSTACIN Cap. Incepta</h3>
            <p>Tamsulosin hydrochloride INN 0.4mg/ capsule. 20's pack: 200.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>PROSTAM Cap. Drug Inter</h3>
            <p>Tamsulosin hydrochloride INN 0.4mg/ capsule. 30's pack: 240.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TAMLOSIN Tab. Orion</h3>
            <p>Tamsulosin hydrochloride INN 0.4mg/tablet.
        20's pack: 200.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TAMOSIN Cap. Supreme</h3>
            <p>Tamsulosin hydrochloride INN 0.4mg/capsule
        20's pack: 200.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>UROFLO Cap. Beximco </h3>
            <p>Tamsulosin hydrochloride INN 0.4mg/ capsule. 20's pack: 200.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>UROLOSIN Tab. General</h3>
            <p>Tamsulosin hydrochloride INN 0.4mg/tablet
        28's pack: 280.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>UROMAX Cap. UniHealth</h3>
            <p>Tamsulosin hydrochloride INN 0.4mg/ capsule. 28's pack: 280.00 MRP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->


<a href="#" data-role="button" data-theme="a">  </a>
    <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> TOLTERODINE TARTRATE: Tablet/Capsule  </h3>
          <p>  Tolterodine is an antimuscarinic drug, used in the treatment of urinary incontinence due to overactive bladder for better urinary control. It is available as tolterodine tartrate INN 1mg, & 2mg film-coated tablet; & tolterodine tartrate INN 2mg, & 4mg extended release capsule.<br><br>

<strong>Mode of action:</strong> Tolterodine is a competitive, specific muscarinic receptor antagonist, which exhibits a selectivity for the urinary bladder over salivary glands. It has a high specificity for muscarinic receptors. A major active metabolite (5-hydroxymethyl derivative) of tolterodine exhibits a pharmacological profile which is similar to that of the parent compound. In extensive metabolisers this metabolite contributes significantly to the therapeutic effect of tolterodine. The effect of treatment can be
expected within 4 weeks.<br><br>

<strong>Ind:</strong> Tolterodine is indicated in the treatment of overactive bladder with symptoms of urinary urgency, frequency, and/or urge incontinence.
<br><br>

<strong>C/I:</strong> Tolterodine is contraindicated in those patients with urinary retention, uncontrolled narrow angle glaucoma, known hypersensitivity to tolterodine or any other component of the drug. <br><br>

<strong>S/E:</strong> Tolterodine may cause mild to moderate antimuscarinic effects, like dryness of mouth, dyspepsia and/or reduced lacrimation.<br><br>

 <strong>Precautions:</strong> Tolterodine should be used with caution in the following conditions- i. at risk for urinary retention, ii. at risk for decreased gastrointestinal motility, iii. with impaired renal function, iv. with impaired hepatic function. Organic reasons for urge and frequency should be considered before treatment.<br><br>

<strong>Pregnancy & lactation:</strong> There are no studies in pregnant women. Therefore, tolterodine should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Use of tolterodine during lactation should be avoided since no data on excretion of the drug into humans breast milk is available.
<br><br>

<strong>Dosage & admin:</strong> 1mg & 2mg tablet (Lc): The recommended dose for tolterodine is 2mg twice daily. In case of troublesome side-effects the dose may be reduced from 2mg to 1mg twice daily. 2mg & 4mg LA capsule: The recommended dose is tolterodine 4mg (one 4mg LA capsule) once daily. The dose may be lowered to 2mg (one 2mg LA capsule) once daily based on individual response & tolerability.For patients with significantly impaired renal or hepatic function, or receiving medication currently or concomitantly with potent CYP3A inhibitors, such as macrolide antibiotics (e.g erythromycin and clarithromycin) or azole antifungal agents (e.g ketoconazole, itraconazole and miconazole), the recommended total daily dose of tolterodine is 2mg (1mg twice daily or 2mg LA capsule once daily). After 6 months the need for further treatment should be considered.<br><br>

<strong>Children:</strong> Safety and effectiveness of tolterodine in children have yet not been established.<br><br>

<strong>Drug inter:</strong> Phamacokinetic interactions are possible with other drugs metabolised by or inhibiting cytochrome P450 2D6 (CYP2D6) or CYP3A. Concomitant treatment with fluoxetine does not result in a clinically significant interaction. Ketoconazole, a potent inhibitor or other CYP3A, significantly increased plasma conce-ntrations of tolterodine when coadministered to poor metabolisers (i.e persons devoid of CYP2D6 metabolic pathway).Clinical studies have shown no interactions with warfarin or combined oral contraceptives (ethinyloestradiol/levonorgestrel).  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DETRUSIN LA Cap. UniHealth/UniMed</h3>
            <p>Tolterodine tartrate INN 4mg/capsule (extended release).<br><br>
        <strong>Dosage & admin:</strong> See above under the text. 20's pack: 300.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TOLORIN Tab. General</h3>
            <p>Tolterodine tartrate INN 2mg/tablet.
        28's pack: 84.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>TOLTER Tab. Renata </h3>
            <p>Tolterodine tartrate INN 1mg & 2mg/tablet.
        1mg x 30's pack: 60.00 MRP 2mg x 30's pack: 90.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>UCOL 2 Tab. Square</h3>
            <p>Tolterodine tartrate INN 2mg/tablet. 30's pack: 90.00 MRP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->

  
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->

<!-- /................page............................ -->


<div data-role="page" id="HAEMODIALYSIS SOLUTIONS" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1> HAEMODIALYSIS SOLUTIONS   </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 


<a href="#" data-role="button" data-theme="a">  </a>
    <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3>Bicarbonate Haemodialysis
Solution   </h3>
          <p> <strong>SOLUTION-A (Acidic Component):</strong><br><br>

Haemodialysis solution-A (acidic component) contains essential salts like sodium chloride, potassium chloride, magnesium chloride, calcium chloride and acetate ions as a buffer. Bicarbonate is best replaced by acetate in order to avoid the release of carbon dioxide into the solution. Bicarbonate is the physiological buffer.<br><br>

<strong>Each 1 litre of concentrated Solution-A contains:</strong>
Sodium chloride BP ......................... 161.43gm <br>
Potassium chloride BP .......................5.49gm <br>
Calcium chloride dihydrate BP .............. 9.75gm <br>
Magnesium chloride hexahydrate BP........... 3.74gm <br>
Glacial acetic acid BP ......................8.85gm <br>
Highly purified water BP ....................q.s. to 1 litre<br><br>

<strong>SOLUTION-B (Bicarbonate Component):</strong><br><br>

Haemodialysis solution-B (bicarbonate component) contains essential salts like sodium chloride and sodium bicarbonate. Bicarbonate is the physiological buffer. Bicarbonate concentrate is used with acid concentrate.<br><br>

<strong>Each 1 litre of concentrated Solution-B contains:</strong><br>
Sodium chloride BP .................... 30.5gm <br>
Sodium bicarbonate BP ................. 66.0gm <br>
Highly purified water BP ..........q.s. to 1 litre<br><br>

<strong>How to prepare mixure dilution:</strong>
In this formulation, the ideal haemodialysis concentrate is achieved by mixing two solutions, solution-A (Acidic component) & solution-B (Bicarbonate component) in a definit ratio. That, 1 part of Solution-A (Acid component) is to be mixed with 1.83 part of Solution-B (Bicarbonate component) & diluted with 34 parts of water of suitable quality.<br><br>

Solution-A (Acidic component).......... 1.00 vol. <br>
Solution-B (Bicarbonate component).....1.83 vol. <br>
Purified water BP ....................34.00 vol.<br><br>


<strong>Ready to use composition:</strong>

After dilution of 1 part of Solution-A (Acid component) with 1.83 parts of Solution-B (Bicarbonate component) & 34 parts of purified water BP or suitable quality water, yield a 'ready to use' bicarbonate haemodialysis solution. The electrolyte concentrations of this diluted 'ready to use' bicarbonate haemodialysis solution stand as following:<br><br>

Sodium ion (Na+)......................75.00 mmol/L<br>
Sodium ion (Na+)......65.00 mmol/L <br>
*Potassium ion (K+)...............2. 00 mmol/L <br>
Calcium ion (Ca++).....................1. 80 mmol/L <br>
Magnesium ion (Mg++).. .... ..0.50 mmol/L <br>
Chloride ion (CI-) .....................81.60 mmol/L <br>
Acetate ion (CH3COO-).......4.00 mmol/L <br>
*Chloride ion (Cl-) ...................26.00 mmol/L <br>
*Bicarbonate (HCO3-)........ .35.00 mmol/L Calc. <br>
Osmolarity ............... 290.90 mOsm/L<br><br>

* (From bicarbonate component)<br>
Note: Electrolyte concentration may need to be adjusted according to patient's requirements.<br><br>

<strong>Ind:</strong> 1. Acute renal failure. 2. Chronic renal failure. 3. Overhydration. 4. To correct electrolyte and acid-base imbalance. 5. In treatment of poisoning. 6. Treatment of renal failure occurring with P. Falciparum infection (malignant tertian malaria).<br><br>

<strong>Precautions:</strong>
1. Do not use solution-A or solution-B alone. Solution-A to be mixed with solution-B for haemodialysis and must be diluted immediately before use with water of suitable quality.<br><br>

2. Untreated tap or portable water is not suitable for the preparation of dialysates. Freshly prepared distilled water obtained under sterile conditions should be used for diluting bicarbonate haemodialysis concentrates. Purified water can be also used but is not recommended to monitor trace elements and chemical elements. Concetration of aluminium ions in purified water must be less than 10mcg/ml. The water also should be free from the chloride and ozone.<br><br>

3. Discard container in case of visible solid particles inside.<br><br>

4. This haemodialysis solution is not for i.v injection or infusion. It is used for haemodialysis purposes only.<br><br>

<strong>Dosage & admin:</strong> Recommended dose: 5 lit. concentrate per dialysis (or as required). Dosage schedule: 2-3 dialaysis per week (or as required). Route of administration: It is used for haemodialysis purposes only.<br><br>

<strong>Storage:</strong> Store in a cool dry place. Do not freeze. Close the container tightly immediately after use. Discard content 96 hours after first opening.   </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIALYTE-A Soln. Popular Acidic</h3>
            <p>component (solution-A) of bicarbonate haemodialysis solution.
        Comp: See above under the text. 10 litres container: 515.00 IP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>DIALYTE-B SoIn. Popular</h3>
            <p>Bicarbonate component (solution-B) of bicarbonate haemodialysis solution. Comp: See above under the text. 10 litres container: 410.00 IP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->


<a href="#" data-role="button" data-theme="a">  </a>
    <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> Acetate Haemodialysis Solution  </h3>
          <p> In acetate formulation of haemodialysis solution, essential salts contained are- sodium chloride, potassium chloride, magnesium chloride, calcium chloride and acetate ions as a buffer.In this formulation, sodium acetate is added as the buffer in place of bicarbonate because, primarily this salt is more soluble in water than the sodium bicarbonate, secondarily this sodium acetate is metabolized in the liver into bicarbonate, which is the physiological buffer.
In acetate formulation (Solution-AC), each 1 litre of concentrated solution contains:<br><br>

Sodium chloride BP .....................198.40gm <br>
Potassium chloride BP....................5.22gm<br>
Calcium chloride dihydrate BP ..............5.15gm <br>
Magnesium chloride hexahydrate BP ....... 3.56gm <br>
Sodium acetate trihydrate BP ....... . 181.01gm <br>
Highly purified water BP ...... .........q.s. to 1 litre <br><br>

<strong>Ind:</strong> 1. Acute renal failure. 2. Chronic renal failure. 3. Overhydration. 4. To correct electrolyte and acid-base imbalance. 5. In treatment of poisoning. 6. Treatment of renal failure occurring with P. Falciparum infection (malignant tertian malaria).<br><br>

<strong>Dilution of solution-AC:</strong><br><br>

1 part of the concentrate haemodialysis solution (soluton-AC) is to be diluted or mixed with 34 parts of water of suitable quality to form a 'ready to use' acetate haemodialysis solution.<br><br>

<strong>Ready to use composition:</strong><br><br>

Electrolytes immediately after dilution with purified water BP:<br>

Sodium ion (Na+) .................... 135.00 mmol/L<br>
 Potassium ion (K+) .................. . 2.00 mmol/L <br>
 Calcium ion (Ca++).........................1.00 mmol/L <br>
 Magnesium ion (Mg++) ................. 0 50 mmol/L <br>
 Chloride ion (Cl-).................. 102.00 mmol/L <br>
 Acetate ion (CH3COO-) ....... 38.00 mmol/L Calc. <br>Osmolarity........................278.50 mOsm/L<br><br>

<strong>Precautions:</strong><br>
1. Solution-AC must be diluted immediately
before use with water of suitable quality.<br><br>

2. Untreated tap or portable water is not suitable for the preparation of dialysates. Freshly prepared distilled water obtained under sterile conditions should be used for diluting bicarbonate haemodialysis concentrates. Purified water can be also used but is not recommended to monitor trace elements and chemical elements. Concetration of aluminium ions in purified water must be less than 10mcg/ml. The water also should be free from the chloride and ozone.<br><br>

3. Discard container in case of visible solid particles inside.<br><br>

4. This haemodialysis solution is not for i.v injection or infusion. It is used for haemodialysis purposes only.<br><br>

<strong>Dosage & admin:</strong> Recommended dose: 5 litres concentrate per dialysis (or as required). Dosage schedule: 2-3 dialaysis per week (or as required).
Route of administration: It is used for haemodialysis purposes only.<br><br>

<strong>Storage:</strong> Store in a cool dry place. Do not freeze. Close the container tightly immediately after use. Discard content 96 hours after first opening.   </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  DIALYTE-C Soln. Popular </h3>
          <p>Acetate formulation (solution-AC) of acetate haemodialysis solution.
          Comp: See above under the text.
          10 litres container: 560.00 IP</p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->
     
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->
	
<!-- /................page............................ -->


<div data-role="page" id="GENITAL" data-theme="a"> <!-- /page snippet -->
 
   <div data-role="header"> <!-- /header -->
      <h1>  DRUGS USING IN GENITAL PROBLEMS  </h1>
      <a  rel="external" href ="Index.html" data-transition="flip" title="home">Home</a>
      <a  rel="external" href ="search.html" data-transition="flip" title="search">search</a>
   </div>  <!-- /header -->


<!-- content -->
  <div data-theme="b"
    data-role="content"> 


<a href="#" data-role="button" data-theme="a"> Drugs acting on the Uterus </a>
    <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ERGOMETRINE MALEATE  </h3>
          <p>  ERGOMETRINE MALEATE: Tablet/Injection<br><br>

           <strong>Ind:</strong> Post partum haemorrhage, active management of third stage of labour, menorrhagia, metrorrhagia following caesarean section or following induced or spontaneous abortion.<br><br>

          <strong>C/I:</strong> 1st and 2nd stages of labour, vascular disease, imparied hepatic and renal function, multiple pregnancy.<br><br>

          <strong>S/E:</strong> Nausea, vomiting, transient hypertension, vasoconstriction.
          <br><br>

          <strong>Precautions:</strong> Toxaemia, cardiac disease, hypertension, sepsis. In case of breech position or multiple pregnancy, ergometrine should be injected after delivery of the last baby.<br><br>

          <strong>Dosage & admin:</strong> By mouth: 0.5-1 mg (onset of action about 8 mins; duration about 1 hour) daily in divided doses.<br>
          By i.m. injection: 200-500mcg (onset about 2 mins).<br>
          By i.v. injection: For emergency control of haemorrhage, 100-500mcg (onset about 1 min) Atonic post partum haemorrhage can be controlled by 125-250mcg. by i.v injection. In menorrhagia, 0.125-0.250mg orally 3-4 times daily.  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>G-ERGOMETRINE Tab. Gonoshasth</h3>
            <p>Methyl ergometrine maleate 0.125mg/ tablet 100's pack: 56.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>G-ERGOMETRINE Inj. Gonoshastha</h3>
            <p>Methyl ergometrine maleate 0.2mg/1ml ampoule: injection
        5 amps pack: 19.40 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>HEMERGIN Tab. Gaco</h3>
            <p>Methyl ergometrine maleate 0.20mg/tablet 100's pack: 64.93 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>HEMERGIN Inj. Gaco</h3>
            <p>Methyl ergometrine maleate 0.2mg/1ml ampoule: injection
        1 ampoule: 7.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>METHERSPAN Tab. Opsonin</h3>
            <p>Methyl ergometrine maleate 0.125mg/tablet 100's pack: 55.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>METHERSPAN Inj. Opsonin</h3>
            <p>Methyl ergometrine maleate 0.2mg/1ml ampoule: injection
        5 amps pack: 15.00 MRP</p>   
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
            <h3>URGOTIN Inj. Chemist</h3>
            <p>Methyl ergometrine maleate 0.2mg/1ml ampoule: injection
        10 amps pack: 30.00 MRP</p>   
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->

      <div data-role="collapsible-set" data-theme="e">
          <div data-role="collapsible"> <!-- collapsible -->
            <h3> OXYTOCIN  </h3>
            <p>  OXYTOCIN: Injection/Nasal spray<br><br>
<strong>Ind:</strong> Induction and augmentation of labour, stimulation of labour where uterine effort is inadequate; management of missed and incomplete abortion; postpartum haemorrhage; also facilitation of lactation (as nasal spray).<br><br>

<strong>C/I:</strong> Mechanical obstruction to delivery; failed trial labour, hypertonic uterine dysfunction; placental praevia, foetal distress, predisposition to amniotic fluid embolism, severe toxaemia.<br><br>

<strong>S/E:</strong> High doses cause violent uterine contractions leading to rupture and foetal distress, arrhythmias, maternal hypertension and subarachnoid haemorrhage, water intoxication.<br><br>

<strong>Precautions:</strong> Cardiovascular disease, hypertension; previous caesarean section; abnormal presentation; multiple pregnancy.<br><br>

<strong>Dosage & admin:</strong> Adult: By slow i.v. infusion- induction and augmentation of labour, as i.v. fluid containing 1 unit per litre, 1-3 milliunits (1-3 ml of fluid or 15-45 drops) per minute, adjusted according to response.Missed abortion, as a fluid containing 10-20 units/500ml given at a rate of 10-30 drops/minute, increased in strength by 10-20 units/500ml every hour to a max. strength of 100 units/500ml. Pospartum haemorrhage, 5-10 units/500ml given at a rate of 15 drops/min. adjusted according to response. By nasal spray- facilitation of lactation, 1 squeeze (about 2 units) into one or both nostrils 2-5 minutes before feeding infant.<br><br>

<strong>Children:</strong>: Not applicable.  </p>
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>OCIN Inj. Opsonin</h3>
              <p>Oxytocin 5 i.u/1ml ampoule: injection 5 amps pack: 39.50 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>PITOCIN Inj. Chemist</h3>
              <p>Oxytocin 5 i.u/1ml ampoule: injection 10 amps pack: 80.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>PITON-S Inj. Nuvista</h3>
              <p>Oxytocin 5 i.u/1ml ampoule: injection 10 amps pack: 105.00 MRP</p>   
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
              <h3>SYNTOCIN Inj. Techno Drugs</h3>
              <p>Oxytocin 5 i.u/1ml ampoule: injection 10 amps pack: 75.00 MRP</p>   
          </div><!-- collapsible -->
        </div><!-- collapsible-set -->


<a href="#" data-role="button" data-theme="a"> Drugs using in Vaginal and Vulval conditions
 </a>
    <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> CLOTRIMAZOLE VT: Vaginal Tablet  </h3>
          <p> Clotrimazole vaginal tablet is available as clotrimazole BP 100mg, 200mg & 500mg tablet with applicator.<br><br>

<strong>Ind:</strong> Vaginal and vulval candidiasis, mixed candidal/trichomonal vaginal infections.<br><br>

<strong>S/E:</strong> Local irritation, possibly including burning, oedema, erythema.<br><br>

<strong>Use & application:</strong> 100mg & 200mg tablet: First infection: In general a 3-day treatment course is sufficient for candida vaginitis. Insert 200mg (100mg 2 tablets or 200mg 1 tablet) high into the vagina with applicator at night, on 3 consecutive days.<br><br>

<strong>Reinfections:</strong> In general a 6-day treatment course is sufficient. Insert 100mg 1 tablet (or if necessary, 200mg 1 tablet) high into the vagina with applicator at night, on 6 consecutive days. If necessary, 100mg 2 tablets can be used daily, (1 in the morning and 1 in the evening) for 6-12 days without any hesitation.
Treatment should be timed so as to avoid the menstrual period.
For prevention of reinfection the partner should be treated locally with clotrimazole cream at the same time.<br><br>

<strong>Children:</strong>: Not applicable.<br><br>

<strong>500mg tablet:</strong> In general, a single dose (500mg) treatment is sufficient for candida vaginitis. Insert 1 tablet high into the vagina with applicator preferably at night.If necessary a second treatment may be carried out. It is recommended that the treatment should be timed so as to avoid the menstrual period.For prevention of reinfection the partner should be treated locally with clotrimazole cream at the same time.<br><br>

<strong>Children:</strong>: Not applicable.   </p>
        </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
            <h3> AFUN VT Tab. Square  </h3>
            <p>   Clotrimazole BP 100mg/tablet (vaginal) with applicator.
          100mg x 6's pack: 60.00 MRP </p>
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
            <h3> CLOZOL VT Tab. Chemist </h3>
            <p> Clotrimazole BP 200mg/tablet (vaginal) with applicator.
          200mg x 3's pack: 60.00 MRP  </p>
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
            <h3> DERMASIM VT Tab. ACI  </h3>
            <p>  Clotrimazole BP 500mg/tablet (vaginal) with applicator.
          Use & application: See above under the text. 500mg x pack: 60.00 MRP  </p>
          </div><!-- collapsible -->

          <div data-role="collapsible"> <!-- collapsible -->
            <h3> NEOSTEN VT Tab. Beximco  </h3>
            <p> Clotrimazole BP 200mg/tablet (vaginal) with applicator.
          200mg x 3's pack: 60.00 IP   </p>
          </div><!-- collapsible -->
      </div><!-- collapsible-set -->

      <div data-role="collapsible-set" data-theme="e">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  ECONAZOLE NITRATE VT: Vaginal Tablet </h3>
          <p>  Econazole vaginal tablet is available as econazole nitrate 150mg tablet with applicator.<br><br>
<strong>Ind:</strong> Candidal vaginitis, vulvitis.<br><br>
<strong>S/E:</strong> Local mild burning or irritation.<br><br>
<strong>Use & application:</strong> Adult, 1 tablet to be inserted high into the vagina for 3 consecutive nights regardless of any intervening menses. Child, not applicable.  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ECONATE-VT Tab. Incepta </h3>
          <p>  Econazole nitrate 150mg/tablet (for vaginal use). 3 tabs pack: 70.00 MRP </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>ECOREN VT Tab. ACI   </h3>
          <p> Econazole nitrate 150mg/tablet (for vaginal use). 3 tabs pack: 72.00 IP   </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>ECOZOL-VT Tab. Opsonin   </h3>
          <p> Econazole nitrate 150mg/tablet (for vaginal use). 3 tabs pack: 70.00 MRP   </p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> ECONAZOLE NITRATE: Gynaecological Cream  </h3>
          <p>  Econazole gynaecological cream is available as Econazole nitrate 1% cream for gynaecological use. <br><br><strong>Ind:</strong> Fungal (candidal) infections of the anogenital area.<br><br>
<strong>S/E:</strong> Local irritation, possibly including burning, oedema, erythema.<br><br>
<strong>Use:</strong> Apply twice daily in the affected area.  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3>  ECONATE-G Crema Incepta </h3>
          <p>  Econazole nitrate 1% cream for gynaecological use. 30gm tube: 70.00 MRP </p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="e">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> METRONIDAZOLE + MICONAZOLE: Vaginal tablet  </h3>
          <p>  Metronidazole 100mg & miconazole nitrate 100mg in each vaginal tablet.<br><br>
<strong>Ind:</strong> Vaginal treatment of female urogenital trichomonas infection, prevention & local therapy of candidiasis.<br><br>
<strong>C/I:</strong> Oral metronidazole is contraindi-cated during pregnancy, possible risk of vaginal treatment with metronidazole should be taken into consideration.<br><br>
<strong>S/E:</strong> Vaginal treatment is concomitantly followed by oral metronidazole. Side effects of oral metronidazole, see under antimicrobial drugs.<br><br> <strong>Dosage & Admin:</strong> In trichomoniasis, concurrently with oral metronidazole treatment 1 vaginal tablet should be inserted high up into the vagina once a day (preparably before going to bed at night) for 10 days. Long- term recovery may be expected only is response to the simultaneous oral treatment of both partners.In candidiasis or otherfungal infections, 1 vaginal tablet has to be inserted high up into the vagina for 10 days.
The vaginal tablet should be slightly moistened before application.  </p>
        </div><!-- collapsible -->

        <div data-role="collapsible"> <!-- collapsible -->
          <h3> AMETROL-VT Tab. Ambee  </h3>
          <p> Metronidazole 100mg & miconazole nitrate 100mg/vaginal tablet.
        10's pack: 110.00 MRP
           </p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="b">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> NYSTAT V.T Acme  </h3>
          <p>  Nystatin 1 lac units: vaginal tablet.<br><br>
<strong>Mode of action:</strong> Nystatin is an antifungal antibiotic, which is both fungistatic & fungicidal in vitro against a variety of yeasts & yeast-like fungi e.g candida albicans. Nystatin probably acts by binding to sterols in the cell membrane of the fungus resulting in change in membrane permeability allowing leakage of intracelluler component.<br><br>
<strong>Ind:</strong> Candida vaginitis such as vulvitis, perineal pruritus, dyspareunia and dysuria etc.<br><br>
<strong>S/E:</strong> Local irritation or burning sensation may occur in a very few cases.
Precautions: If irritation or sensitization develops, treatment should be discontinued. During pregnancy applicator should be used carefully. <br><br><strong>Dosage & Admin:</strong> 1 or 2 Nystat V.T. shouldbe inserted daily at night. This should be continued for 2 weeks and even it should be continued during menstrual period.
15's pack: 29.25 MRP  </p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->



      <div data-role="collapsible-set" data-theme="e">
        <div data-role="collapsible"> <!-- collapsible -->
          <h3> TYCON Suppo. Acme  </h3>
          <p>  Tioconazole BP 300mg/stick: vaginal suppository.
Tioconazole is a member of the imidazole class of antifungal agents.<br><br>
<strong>Ind:</strong> Vulvo-vaginal candidiasis.<br><br>
<strong>C/I:</strong> History of sensitization to tioconazole or to any of the other components of vaginal suppository or to other imidazole antifungal agents. <br><br><strong>S/E:</strong> The most frequently observed local side- effects are burning (6%) and itching (5%).
Isolated local vaginal symptoms such as irritation, discharge, labial swelling, vaginal pain, dysuria, nocturia, dyspareunia, dryness of vaginal secretions, vulva edema are observed. Precautions: Constituents of the vaginal suppository may be incompatible with rubber in both contraceptive condoms and diaphragms. Skin and mucosal sensitization may occur. If so, use of tioconazole vaginal suppository should be discontinued.<br><br>
<strong>Pregnancy & lactation: </strong>There are no adequate and well controlled studies which establish the safety of tioconazole vaginal suppository in pregnant women. So, the use of vaginal suppository during pregnancy should be considered only if the potential benefit outweighs the potential risk to the fetus.
Tioconazole should not be used by nursing women unless the potential benefit outweighs the possible risk.<br><br>
<strong>Dosage & admin:</strong> One 300mg suppository to be used intravaginally as single dose, preferably at bedtime for one night only; for- patients who are improved but not completely cured a second application may be effective if administered one week later.
Vaginal candidiasis may be accompanied by vulval infection. Therefore, concomitant local treatment with the tioconazole cream should be applied to the vulva and as far as the anal region once or twice daily for up to 7 days (as needed) is advisable. To treat the male partner, a small amount of cream should be applied onto the glans penis once or twice daily for up to 7 days as needed or to help prevent reinfection by the partner.
5's pack: 300.00 MRP  </p>
        </div><!-- collapsible -->
      </div><!-- collapsible-set -->


      <a href="#" data-role="button"  data-theme="a">MIXED PREPNS  </a>
            <div data-role="collapsible-set" data-theme="b">
              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GYNOMIX Soft Cap. Drug Inter  </h3>
                <p>  Each soft gelatin capsule (vaginal suppository) contains- neomycin sulphate BP 35,000 i.u, polymyxin B sulphate BP 35,000 i.u, nystatin BP 100, 000 i.u, acetarsol BP 150mg and postassium sorbate BP 7.5mg + dimethylpolysiloxane BP 2gm as excipients.<br><br>
<strong>Ind:</strong> Vaginal trichomoniasis, mixed vaginal infections, vaginal leucorrhoeas (mycotic or bacterial).<br><br>
<strong>S/E:</strong> Skin rash, urticaria may occur rarely. Precautions: Impaired renal function.<br><br>
<strong>Dosage & Admin:</strong> Use in vagina 1 capsule at night (bed time) for 12 days or as directed by the physician.<br><br>
6 caps pack: 145.56 MRP  </p>
              </div><!-- collapsible -->

              <div data-role="collapsible"> <!-- collapsible -->
                <h3> GYNORIL Suppos. Opsonin  </h3>
                <p> Each vaginal suppository contains- neomycin sulphate BP 35,000 i.u, polymyxin B sulphate BP 35,000 i.u, nystatin BP 100, 000 i.0 & metroni- dazole BP 200mg: suppository for vaginal use. <br><br><strong>Ind:</strong> vaginal trichomoniasis, mixed vaginal infections, vaginal leucorrhoeas (mycotic or bacterial). <br><br><strong>S/E: </strong>skin rash, urticaria may occur rarely. <strong>Precautions:</strong> impaired renal function.<br><br>
<strong>Dosage & Admin:</strong> 1 suppository to be introduced into the vagina at night (bed time) for 12 days or as directed by the physician. 12's pack: 288.00 MRP   </p>
              </div><!-- collapsible -->
            </div><!-- collapsible-set -->

            <a href="#" data-role="button"  data-theme="a"> OTHER PREPNS </a>
                  <div data-role="collapsible-set" data-theme="b">
                    <div data-role="collapsible"> <!-- collapsible -->
                      <h3> HEXITANE Obstetric Cream ACI  </h3>
                      <p> Chlorhexidine gluconate 1% w/w cream in a pourable water-miscible basis.<br><br>
<strong>Ind:</strong> use in obstetrics as a vaginal
lubricant and for application to the vulva and perineum during labour.<br><br>
<strong>Use:</strong> to be applied liberally to the
skin on and around vulva, to hand, prior to vaginal application
60ml bot: 31.00 MRP   </p>
                    </div><!-- collapsible -->
                  </div><!-- collapsible-set -->
   
    </div><!-- content --> 


   <div data-role="footer" data-position="fixed">
      <h4></h4>
   </div>
</div>  <!-- /page snippet -->


</body> 
</html> 
